Oxford Biodyn Share News (OBD)

EARNINGS: MS International hails record profit; Dekel loss narrows

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Monday and not separately reported by Alliance News:

Oxford BioDynamics gets UK lab accredited as clinical facility

(Sharecast News) - Oxford BioDynamics announced on Friday that its Oxford-based laboratory had been accredited by the UK Accreditation Service (UKAS) as a clinical facility under ISO 15189, enabling it to process 'EpiSwitch' clinical tests in the UK.

Oxford BioDynamics expands UK insurance partnership with Bupa

(Alliance News) - Oxford BioDynamics PLC on Thursday announced an expanded strategic agreement with UK health insurance provider Bupa.

LONDON MARKET CLOSE: FTSE 100 outperforms; New York stocks rise

(Alliance News) - Blue-chip stocks in Europe recovered lost ground to end largely higher on Friday afternoon, though the FTSE 100 outperformed.

Oxford Biodynamics shares dive as loss widens despite revenue rise

(Alliance News) - Oxford Biodynamics PLC shares tumbled 10% on Friday, after the firm reported its loss widened in 2024 despite a rise in revenue.

AIM WINNERS & LOSERS: Oxford BioDynamics and Benchmark slump

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Friday.

LONDON MARKET OPEN: "Tariff bombshell" sends European stocks lower

(Alliance News) - European equities traded lower on Friday morning, after Asian stocks sunk on the latest tariff barb by US President Donald Trump.

UK earnings, trading statements calendar - next 7 days

Oxford BioDynamics inks distribution deal with Romanian medical firm

(Alliance News) - Oxford BioDynamics PLC on Wednesday said it has partnered with Regina Maria Private Health Network, the largest medical services provider in Romania, on the distribution of its blood test products.

Oxford BioDynamics signs distribution deal with Romania healthcare provider

(Sharecast News) - Oxford BioDynamics announced on Wednesday that it has signed a distribution agreement with Regina Maria, Romania's largest private healthcare provider, to offer its EpiSwitch PSE and CiRT blood tests to physicians and patients across the country.

Oxford BioDynamics upbeat on publication of EpiSwitch study

(Sharecast News) - Oxford BioDynamics announced the publication of a multi-institutional clinical study on Wednesday, confirming the accuracy of its EpiSwitch Colorectal No-Stool Test (NST) in detecting colorectal cancer and precancerous polyps using a blood sample.

AIM WINNERS & LOSERS: Arrow Exploration well disappoints

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Wednesday.

IN BRIEF: Oxford BioDynamics raises GBP350,000 via retail offer

Oxford BioDynamics PLC - Oxford, England-based biotechnology company has two blood testing products on market, the PSE prostate cancer screening test and the CiRT checkpoint inhibitor response test - Raises GBP350,000 via retail share offer at 0.5 pence per share. This is in addition to GBP7.0 million raised by placing and subscription at the same price, announced on Wednesday.

Oxford BioDynamics raises £7.35m through placing, subscription and retail offer

(Sharecast News) - Oxford BioDynamics, a precision clinical diagnostics company leveraging its 'EpiSwitch 3D' genomics platform, announced the successful completion of its fundraising initiative on Friday.

IN BRIEF: Oxford BioDynamics launches GBP6.5 million fund raise

Oxford BioDynamics PLC - Oxford, England-based biotechnology company has two blood testing products on market, the PSE prostate cancer screening test and the CiRT checkpoint inhibitor response test - Plans to raise GBP6 million via placing at a minimum price of 0.5 pence per share, a subscription and GBP500,000 cornerstone investment by OAK Securities. Further, seeks to raise GBP500,000 via retail offer. The placing will be conducted through an accelerated bookbuilding process. Proceeds will be used as working capital to support the continued commercial development of the EpiSwitch product line through partnerships and collaborations with diagnostic and pharmaceutical companies and direct sales as appropriate.